Novartis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate.

CEO

Vasant Narasimhan

CEOVasant Narasimhan

Employees

75,883

Employees75,883

Headquarters

Basel, Basel-Stadt (Basle Town)

HeadquartersBasel, Basel-Stadt (Basle Town)

Founded

1996

Founded1996

Employees

75,883

Employees75,883

NVS Key Statistics

Market cap

269.31B

Market cap269.31B

Price-Earnings ratio

18.20

Price-Earnings ratio18.20

Dividend yield

2.59%

Dividend yield2.59%

Average volume

1.02M

Average volume1.02M

High today

$128.05

High today$128.05

Low today

$127.35

Low today$127.35

Open price

$127.53

Open price$127.53

Volume

846.81K

Volume846.81K

52 Week high

$130.46

52 Week high$130.46

52 Week low

$96.06

52 Week low$96.06

NVS News

Benzinga 2d

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. TRML shares surged Tuesday after Novartis AG NVS announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss dr...

TipRanks 2d

Tourmaline Bio downgraded to Neutral from Outperform at Wedbush

Wedbush downgraded Tourmaline Bio (TRML) to Neutral from Outperform with an unchanged $48 price target after the company entered into a merger agreement with No...

TipRanks 2d

Novartis Seals $1.4B Deal with Tourmaline Bio to Bolster Heart Disease Portfolio

Novartis (NVS), the Swiss pharma giant, said on Tuesday it will acquire Tourmaline Bio (TRML) for $48 per share, valuing the New York-based biopharma at $1.4 bi...

Analyst ratings

64%

of 25 ratings

Buy

20%

Hold

64%

Sell

16%

More NVS News

TipRanks 3d

Novartis price target raised to CHF 105 from CHF 100 at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to CHF 105 from CHF 100 and keeps an Equal Weight rating on the share...